Industry
Samsung Electronics, Harvard Medical School to study monitoring side effects of obesity drugs with Galaxy Watch
Samsung Electronics said on Wednesday it will pursue a joint study with Massachusetts General Hospital, affiliated with Harvard Medical School, to track physical changes in patients taking GLP-1 obesity drugs using the Galaxy Watch. The study will use the Galaxy Watch8’s BioActive Sensor and follow 100 adults starting weight-loss drug therapy. Researchers will compare a group using the watch for body composition and activity monitoring with a standard-treatment group, alongside DXA scans.